JP2015506665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506665A5 JP2015506665A5 JP2014525227A JP2014525227A JP2015506665A5 JP 2015506665 A5 JP2015506665 A5 JP 2015506665A5 JP 2014525227 A JP2014525227 A JP 2014525227A JP 2014525227 A JP2014525227 A JP 2014525227A JP 2015506665 A5 JP2015506665 A5 JP 2015506665A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- smyd2
- test substance
- functional equivalent
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims 40
- 239000000126 substance Substances 0.000 claims 35
- 206010028980 Neoplasm Diseases 0.000 claims 23
- 201000011510 cancer Diseases 0.000 claims 23
- 238000000034 method Methods 0.000 claims 20
- 230000027455 binding Effects 0.000 claims 16
- 101000708645 Homo sapiens N-lysine methyltransferase SMYD2 Proteins 0.000 claims 14
- 102100032806 N-lysine methyltransferase SMYD2 Human genes 0.000 claims 14
- 239000003153 chemical reaction reagent Substances 0.000 claims 13
- 230000010261 cell growth Effects 0.000 claims 12
- 230000011987 methylation Effects 0.000 claims 12
- 238000007069 methylation reaction Methods 0.000 claims 12
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 claims 10
- 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 claims 10
- 230000005764 inhibitory process Effects 0.000 claims 10
- 230000002265 prevention Effects 0.000 claims 10
- 101150031513 Smyd2 gene Proteins 0.000 claims 9
- 238000012216 screening Methods 0.000 claims 9
- 102100039869 Histone H2B type F-S Human genes 0.000 claims 7
- 108010033040 Histones Proteins 0.000 claims 7
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 claims 7
- 239000000758 substrate Substances 0.000 claims 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 6
- 239000004472 Lysine Substances 0.000 claims 6
- 230000004071 biological effect Effects 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 230000026731 phosphorylation Effects 0.000 claims 5
- 238000006366 phosphorylation reaction Methods 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 102100034523 Histone H4 Human genes 0.000 claims 3
- 102000006947 Histones Human genes 0.000 claims 3
- 108700008625 Reporter Genes Proteins 0.000 claims 3
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 claims 3
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 102000016397 Methyltransferase Human genes 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 claims 1
- 101150002130 Rb1 gene Proteins 0.000 claims 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical group O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims 1
- 229960001570 ademetionine Drugs 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566193P | 2011-12-02 | 2011-12-02 | |
| US61/566,193 | 2011-12-02 | ||
| PCT/JP2012/004232 WO2013080400A1 (en) | 2011-12-02 | 2012-06-29 | Smyd2 as a target gene for cancer therapy and diagnosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506665A JP2015506665A (ja) | 2015-03-05 |
| JP2015506665A5 true JP2015506665A5 (enExample) | 2015-08-06 |
| JP6051373B2 JP6051373B2 (ja) | 2016-12-27 |
Family
ID=48534908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014525227A Expired - Fee Related JP6051373B2 (ja) | 2011-12-02 | 2012-06-29 | 癌の治療および診断の標的遺伝子としてのｓｍｙｄ２ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20140308678A1 (enExample) |
| EP (1) | EP2785870B1 (enExample) |
| JP (1) | JP6051373B2 (enExample) |
| WO (1) | WO2013080400A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016061131A1 (en) * | 2014-10-14 | 2016-04-21 | The J. David Gladstone Institutes | Compositions and methods for reactivating latent immunodeficiency virus |
| US10604786B2 (en) * | 2015-05-20 | 2020-03-31 | Pamgene Bv | Method for predicting the response of melanoma patients to targeted pharmacotherapy |
| US20250257361A1 (en) * | 2022-11-09 | 2025-08-14 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating liver diseases with sirnas targeting smyd2 |
| CN116789750B (zh) * | 2023-08-17 | 2023-11-10 | 中国农业大学 | 预防和/或治疗宫颈癌的多肽及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE356223T1 (de) | 2001-09-25 | 2007-03-15 | Japan President Univ Tokyo | Gen und protein mit bezug zu hepatozellulärem karzinom |
| US20070111255A1 (en) * | 2003-12-02 | 2007-05-17 | Komatsu Etal | Antibodies recognizing methyllysine, process for producing the same and utilization thereof |
| TWI350373B (en) | 2004-01-23 | 2011-10-11 | Oncotherapy Science Inc | Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators |
| JP5429735B2 (ja) * | 2009-03-25 | 2014-02-26 | 富士フイルム株式会社 | 食道癌の検出方法及び抑制剤 |
-
2012
- 2012-06-29 EP EP12852815.5A patent/EP2785870B1/en not_active Not-in-force
- 2012-06-29 WO PCT/JP2012/004232 patent/WO2013080400A1/en not_active Ceased
- 2012-06-29 JP JP2014525227A patent/JP6051373B2/ja not_active Expired - Fee Related
- 2012-06-29 US US14/354,813 patent/US20140308678A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures | |
| Sharma et al. | Arginine citrullination at the C-terminal domain controls RNA polymerase II transcription | |
| Thedieck et al. | PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis | |
| Nijtmans et al. | The mitochondrial PHB complex: roles in mitochondrial respiratory complex assembly, ageing and degenerative disease | |
| Li et al. | A human-specific de novo protein-coding gene associated with human brain functions | |
| Aggarwal et al. | Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase | |
| Schorderet et al. | Structural and functional differences in the long non-coding RNA hotair in mouse and human | |
| Basak et al. | The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation | |
| Piwko et al. | RNAi-based screening identifies the Mms22L–Nfkbil2 complex as a novel regulator of DNA replication in human cells | |
| Lou et al. | The other side of the coin: The tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND–CDK4/6–RB axis | |
| Sabra et al. | The Tudor protein survival motor neuron (SMN) is a chromatin-binding protein that interacts with methylated lysine 79 of histone H3 | |
| Khosla et al. | miR‐26b‐5p helps in EpCAM+ cancer stem cells maintenance via HSC71/HSPA8 and augments malignant features in HCC | |
| JP2013543114A5 (enExample) | ||
| Rabjerg et al. | Molecular characterization of clear cell renal cell carcinoma identifies CSNK 2A1, SPP 1 and DEFB 1 as promising novel prognostic markers | |
| RU2012148125A (ru) | Биомаркеры на основе мультиракового ассоциированного с инвазией механизма | |
| JP2016536012A5 (enExample) | ||
| WO2012075506A3 (en) | Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses | |
| JP2008538494A5 (enExample) | ||
| Yu et al. | Overexpression of TONSL might be an independent unfavorable prognostic indicator in hepatocellular carcinoma | |
| Stoyanov et al. | Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine hepatocarcinogenesis | |
| JP2010528584A5 (enExample) | ||
| Lardenois et al. | Quantitative proteome profiling of dystrophic dog skeletal muscle reveals a stabilized muscular architecture and protection against oxidative stress after systemic delivery of MuStem cells | |
| JP2010502192A5 (enExample) | ||
| Walter et al. | microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma | |
| Lau et al. | ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling |